Primary CNS lymphomas (PCNSL) represent a subgroup of malignancies with specific characteristics, aggressive course, and unsatisfactory outcome in contrast with other lymphomas comparable for tumour burden and/or histological type. Despite a high chemo- and radiosensitivity, remissions are frequently shortlasting, mainly because the blood brain-barrier limits the access of many drugs to the CNS...

Background. Lymphoma of the central nervous system (CNS), both primary and secondary, is a rare but very aggressive type non-Hodgkin’s lymphoma. Primary CNS lymphoma (PCNSL) refers to cases confined parenchyma, dura mater, leptomeninges, cranial nerves, spinal cord or intraocular region. The prognosis PCNSL has been dismal with an overall survival 1.5 months without treatment 5-year rate 30%. D...

BACKGROUND At present there is no standard of care for patients with primary central nervous system lymphoma (PCNSL) because of the difficulty in delivering therapeutically effective doses of drugs to the intracellular site of the target PCNSL. Here we report the use of an iron oxide nanoparticle to promote the internalization of a PCNSL targeting antibody by target cells. METHODS Iron oxide ...

Abstract INTRODUCTION Primary central nervous system lymphoma (PCNSL) is a rare and aggressive disease. Standard induction therapy for PCNSL consists of high-dose methotrexate-based (HD-MTX) regimen. For relapsed or refractory primary CNS (r/r PCNSL), most the non-standard treatment regimens including additional chemotherapy, stem cell transplant, whole brain radiation (WBRT) may not reach long...

Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity specificity of myeloid differentiation response (88) (MYD88) L265P mutation (mut-MYD88) interleukin-10 (IL-10) cerebrospinal fluid (CSF) both newly diagnosed (n = 36) relapsed 27) PCNSL 162 control...

Abstract Although high-dose methotrexate (HD-MTX)-based chemotherapy, such as rituximab, HD-MTX, procarbazine and vincristine (R-MPV) regimen, has significantly prolonged the survival of patients with primary central nervous system lymphoma (PCNSL), predictive factors for response to R-MPV have not yet been investigated. Then, we investigated correlation MYD88 L265P CD79B Y196 mutations, which ...

BACKGROUND Primary central nervous system lymphoma (PCNSL) is a rare, aggressive brain neoplasm that accounts for roughly 2-6% of primary brain tumors. In contrast, glioblastoma (GBM) is the most frequent and severe glioma subtype, accounting for approximately 50% of diffuse gliomas. The aim of the present study was to evaluate morphological MRI characteristics in histologically-proven PCNSL an...

It is suspected that primary central nervous system lymphoma (PCNSL) rates are increasing among immunocompetent people. We estimated PCNSL trends in incidence and survival among immunocompetent persons by excluding cases among human immunodeficiency virus (HIV)-infected persons and transplant recipients. PCNSL data were derived from 10 Surveillance, Epidemiology and End Results (SEER) cancer re...